| Literature DB >> 32944315 |
Xiao-Kun Li1, Yang Xu2, Zhuang-Zhuang Cong3, Hai Zhou2, Wen-Jie Wu4, Yi Shen1,3.
Abstract
BACKGROUND: Robotic system was recently introduced to assist surgeons in performing thymectomy. However, whether robot-assisted thoracoscopic thymectomy (RATT) could replace video-assisted thoracoscopic thymectomy (VATT) and be considered as a superior treatment for thymic epithelial tumors is still controversial. The aim of this study was to evaluate the progression-free survival (PFS) and short-term clinical outcomes in patients undergoing RATT or VATT by comparing the matched two groups after performing propensity score analysis.Entities:
Keywords: Robot-assisted thoracoscopic thymectomy (RATT); progression-free survival (PFS); propensity score matching; video-assisted thoracoscopic thymectomy (VATT)
Year: 2020 PMID: 32944315 PMCID: PMC7475562 DOI: 10.21037/jtd-20-1065
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895
Figure 1The surgical incisions.
Figure 2The procedure of RATT, with maximum removal of superior poles by gradual pulling down and resection. RATT, robot-assisted thoracoscopic thymectomy.
Baseline characteristics before matching
| Characteristics | RATT (n=60) | VATT (n=235) | Statistical analysis | P value |
|---|---|---|---|---|
| Age | 53.72±13.11 | 52.23±12.56 | Unpaired | 0.42 |
| Gender | Chi-square | 0.89 | ||
| Man | 30 | 114 | ||
| Female | 30 | 121 | ||
| Tumor size | 5.50±2.38 | 6.05±3.75 | Unpaired | 0.14 |
| Organization histologic classification | Chi-square test | 0.65 | ||
| A | 4 | 25 | ||
| AB | 6 | 20 | ||
| B1 | 12 | 49 | ||
| B2 | 24 | 89 | ||
| B3 | 9 | 43 | ||
| C | 5 | 9 | ||
| Masaoka stages | Chi-square test | 0.65 | ||
| I | 16 | 80 | ||
| IIa | 23 | 85 | ||
| IIb | 19 | 66 | ||
| III | 2 | 4 | ||
| MG | 4 | 13 | Chi-square test | 0.73 |
| Adjuvant therapy | 41 | 140 | Chi-square test | 0.21 |
RATT, robot-assisted thoracoscopic thymectomy; VATT, video-assisted thoracoscopic thymectomy; MG, myasthenia gravis.
Clinical outcomes before matching
| Clinical outcomes | RATT (n=60) | VATT (n=235) | Statistical analysis | P value |
|---|---|---|---|---|
| Surgical time (min) | 102.10±14.125 | 107.83±15.616 | Unpaired | 0.01 |
| Postoperative complications | 2 | 10 | Chi-square | 0.75 |
| Duration of chest tube insertion (days) | 2.23±0.504 | 2.34±0.649 | Unpaired | 0.22 |
| Median volume of drainage (mL) | 209.50±52.380 | 217.04±54.214 | Unpaired | 0.33 |
| Postoperative hospital stay (days) | 4.48±2.376 | 4.64±2.675 | Unpaired | 0.68 |
RATT, robot-assisted thoracoscopic thymectomy; VATT, video-assisted thoracoscopic thymectomy.
Figure 3PFS curves of the unmatched patients undergoing thymectomy stratified by surgical type (P=0.248). PFS, progression-free survival; RATT, robot-assisted thoracoscopic thymectomy; VATT, video-assisted thoracoscopic thymectomy.
Univariable and multivariable analysis
| Characteristics | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age | 1.032 (1.007–1.058) | 0.012 | 1.032 (1.004–1.060) | 0.023 | |
| Gender | 0.216 | 1.161 | |||
| Man | Reference | Reference | |||
| Female | 1.467 (0.800–2.691) | 1.611 (0.827–3.138) | |||
| Tumor size | 0.914 (0.834–1.002) | 0.055 | 0.935 (0.833–1.049) | 0.253 | |
| Organization histologic classification | <0.001 | <0.001 | |||
| A–B2 | Reference | Reference | |||
| B3–C | 0.046 (0.021–0.102) | 0.147 (0.064–0.341) | |||
| Original Masaoka stages | <0.001 | 0.024 | |||
| I–IIa | Reference | Reference | |||
| IIa–III | 0.048 (0.012–0.200) | 0.175 (0.039–0.792) | |||
| MG | 0.008 (0.002–0.039) | <0.001 | 0.041 (0.009–0.179) | <0.001 | |
| Adjuvant therapy | 0.071 (0.021–0.234) | <0.001 | 0.292 (0.080–1.070) | 0.063 | |
| Surgical type | |||||
| VATT | Reference | Reference | |||
| RATT | 0.624 (0.278–1.403) | 0.254 | 0.461 (0.200–1.061) | 0.069 | |
MG, myasthenia gravis; RATT, robot-assisted thoracoscopic thymectomy; VATT, video-assisted thoracoscopic thymectomy.
Figure 4PFS curves of the matched patients undergoing thymectomy stratified by surgical type (P=0.158). PFS, progression-free survival.
Baseline characteristics after matching
| Characteristics | RATT (n=60) | VATT (n=60) | Statistical analysis | P value |
|---|---|---|---|---|
| Age | 53.72±13.11 | 51.22±12.21 | Paired t-test | 0.29 |
| Gender | McNemar’s test | 1.00 | ||
| Man | 30 | 30 | ||
| Female | 30 | 30 | ||
| Tumor size | 5.50±2.38 | 5.277±2.94 | Paired t-test | 0.60 |
| Organization histologic classification | Extensions thereof of McNemar’s test | 0.87 | ||
| A | 4 | 5 | ||
| AB | 6 | 4 | ||
| B1 | 12 | 8 | ||
| B2 | 24 | 27 | ||
| B3 | 9 | 14 | ||
| C | 5 | 2 | ||
| Original Masaoka stages | Extensions thereof of McNemar’s test | 0.83 | ||
| I | 16 | 20 | ||
| IIa | 23 | 25 | ||
| IIb | 19 | 14 | ||
| III | 2 | 1 | ||
| MG | 4 | 3 | McNemar’s test | 1.00 |
| Adjuvant therapy | 41 | 40 | McNemar’s test | 1.00 |
RATT, robot-assisted thoracoscopic thymectomy; VATT, video-assisted thoracoscopic thymectomy; MG, myasthenia gravis.
Clinical outcomes after matching
| Clinical outcomes | RATT (n=60) | VATT (n=60) | Statistical analysis | P value |
|---|---|---|---|---|
| Surgical time (min) | 102.10±14.13 | 106.22±13.24 | Paired | 0.042 |
| postoperative complications | 2 | 2 | McNemar’s test | 1.00 |
| Duration of chest tube insertion (days) | 2.23±0.504 | 2.34±0.649 | Paired | 0.21 |
| Median volume of drainage (mL) | 209.50±52.380 | 217.04±54.214 | Paired | 0.13 |
| Postoperative hospital stay (days) | 4.48±2.376 | 4.68±2.740 | Paired | 0.65 |
RATT, robot-assisted thoracoscopic thymectomy; VATT, video-assisted thoracoscopic thymectomy.
Figure 5PFS curves of the matched patients undergoing thymectomy stratified by surgical type (P=0.095). PFS, progression-free survival; RATT, robot-assisted thoracoscopic thymectomy; VATT, video-assisted thoracoscopic thymectomy.